Cladribine (2CdA), an adenosine deaminase inhibitor, is utilized in the treatment of lymphoproliferative diseases.

Adenosine deaminase (U266 cells):2.43 μM, Adenosine deaminase (RPMI8226 cells):0.75 μM, Adenosine deaminase (MM1.S cells):0.18 μM

In adult zebrafish, intraperitoneal injection of Cladribine (0.7-3.5 mM) was found to inhibit the concentration levels of ATP in RBCs (Red Blood Cells).

Cladribine inhibits cell growth in primary mast cells (MC) and the MC line HMC-1. It also reduces cell migration ability in CD14+ monocytes as well as CD4+ and CD8+ T lymphocytes. Additionally, Cladribine suppresses cell proliferation in U266, RPMI8226, and MM1.S cells in a dose-dependent manner.

The non-radioactive cell proliferation kit is used to determine cell viability. In brief, Human MM cell line U266, RPMI8226 and MM1.S are seeded onto 96-well plates with either 0.1 mL complete medium (5% FBS) as control, or 0.1 mL of the same medium containing a series of doses of cladribine, and incubated for 72 hours. After reading all wells at 490 nm with a micro-plate reader, the percentages of surviving cells from each group relative to controls, defined as 100% survival, are determined by reduction of MTS.(Only for Reference)